| Literature DB >> 28958335 |
Jacob S Koruth1, Anuradha Lala2, Sean Pinney3, Vivek Y Reddy1, Srinivas R Dukkipati4.
Abstract
The clinical use of ivabradine has and continues to evolve along channels that are predicated on its mechanism of action. It selectively inhibits the funny current (If) in sinoatrial nodal tissue, resulting in a decrease in the rate of diastolic depolarization and, consequently, the heart rate, a mechanism that is distinct from those of other negative chronotropic agents. Thus, it has been evaluated and is used in select patients with systolic heart failure and chronic stable angina without clinically significant adverse effects. Although not approved for other indications, ivabradine has also shown promise in the management of inappropriate sinus tachycardia. Here, the authors review the mechanism of action of ivabradine and salient studies that have led to its current clinical indications and use.Entities:
Keywords: angina; atrial fibrillation; bradycardia; coronary artery disease; funny current; heart failure
Mesh:
Substances:
Year: 2017 PMID: 28958335 DOI: 10.1016/j.jacc.2017.08.038
Source DB: PubMed Journal: J Am Coll Cardiol ISSN: 0735-1097 Impact factor: 24.094